Other case reports do not indicate a worse clinical course in COVID-19 patients exposed to anti-IgE omalizumab (Lommatzsch et al., 2020) and, anti-IL-5R benralizumab (Renner et al., 2020a; Renner et al., 2020b). This evidence concerns the gene IL5RA and COVID-19.